- Home
- ATHA vs GENK Comparison
ATHA vs GENK Comparison
Compare ATHA & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATHA | GENK |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 16.3M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ATHA | GENK |
|---|---|---|
| Price | $3.87 | $2.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 19.1K | ★ 52.5K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $217,449,000.00 |
| Revenue This Year | N/A | $11.49 |
| Revenue Next Year | N/A | $13.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $2.20 | $2.20 |
| 52 Week High | $6.18 | $8.45 |
Technical Indicators
Market Signals| Indicator | ATHA | GENK |
|---|---|---|
| Relative Strength Index (RSI) | 40.18 | 39.07 |
| Support Level | $3.84 | $2.20 |
| Resistance Level | $4.34 | $2.41 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 5.98 | 30.77 |
Price Performance
Historical ComparisonAbout ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.